Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

David Roife

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9052-2248; OpenAlex author ID A5028941145. Sources: OpenAlex.

Their work

Papers
14 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 14

  1. Editor's Note: Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1527↗
  2. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  3. Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Co-author DOI 10.1038/s41419-021-03970-8↗
  4. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pa… First author DOI 10.1186/s12885-020-07182-9↗
  5. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
  6. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. First author DOI 10.1016/j.sopen.2019.05.004↗
  7. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth. Co-author DOI 10.1038/onc.2017.125↗
  8. Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarci… First author DOI 10.1158/1535-7163.mct-16-0526↗
  9. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. First author DOI 10.1038/onc.2016.20↗
  10. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. First author DOI 10.1158/1078-0432.ccr-15-2780↗
  11. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-2936↗
  12. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Co-author DOI 10.1038/labinvest.2014.143↗
  13. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Co-author DOI 10.1158/1078-0432.ccr-14-0970↗
  14. Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. Co-author PMID 25202045↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jason B. Fleming · 14 shared papers, 2014–2024 · strength 1.20
  2. Ya’an Kang · 13 shared papers, 2014–2024 · strength 1.09
  3. Mayrim V. Rios Perez · 8 shared papers, 2016–2024 · strength 0.77
  4. Bingbing Dai · 8 shared papers, 2016–2024 · strength 0.77
  5. Xinqun Li · 8 shared papers, 2014–2024 · strength 0.72
  6. Matthew H. G. Katz · 5 shared papers, 2014–2022 · strength 0.32
  7. Huamin Wang · 5 shared papers, 2014–2022 · strength 0.32
  8. Paul J. Chiao · 3 shared papers, 2016–2022 · strength 0.24
  9. Michela Capello · 2 shared papers, 2020–2022 · strength 0.19
  10. Ehsan Irajizad · 2 shared papers, 2020–2022 · strength 0.19
  11. Jody V. Vykoukal · 2 shared papers, 2020–2022 · strength 0.19
  12. Laura R. Prakash · 2 shared papers, 2020–2022 · strength 0.19
  13. Johannes Francois Fahrmann · 2 shared papers, 2020–2022 · strength 0.19
  14. Samir Hanash · 2 shared papers, 2020–2022 · strength 0.19
  15. Anirban Maitra · 2 shared papers, 2020–2022 · strength 0.19
  16. Rei Suzuki · 3 shared papers, 2014–2016 · strength 0.14
  17. Ryan Michael Thomas · 3 shared papers, 2014–2016 · strength 0.13
  18. Deyali Chatterjee · 3 shared papers, 2014–2016 · strength 0.13
  19. Jenying Deng · 1 shared paper, 2021 · strength 0.12
  20. Michael P. Kim · 1 shared paper, 2021 · strength 0.12
  21. Yihui Chen · 1 shared paper, 2022 · strength 0.12
  22. Eugene Jon Koay · 2 shared papers, 2016–2017 · strength 0.12
  23. Gilbert Zvikomborero Murimwa · 1 shared paper, 2020 · strength 0.11
  24. David T. Pointer · 1 shared paper, 2020 · strength 0.11
  25. José M. Pimiento · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.